Every 10-Q that Milestone Pharmaceuticals (MIST) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow MIST and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MIST filings page.
Milestone Pharmaceuticals reported its first commercial sales of CARDAMYST (etripamil) nasal spray in the United States, generating $0.6 million in product revenue for the quarter and $0.8 million for the first half of 2026. The company remains focused on CARDAMYST’s PSVT launch, advancing etripamil for AFib-RVR, and ex-U.S. regulatory and partnering activities.
The business is still highly loss‑making: net loss was $28.6 million for the quarter and $54.7 million year‑to‑date, driven mainly by a sharp increase in selling, general and administrative expenses to $22.6 million in the quarter as commercialization ramps. Operating cash outflow for the first half was $38.8 million.
Liquidity is currently strong. As of June 30, 2026, Milestone held $170.6 million in cash, cash equivalents and short‑term investments, and recorded a royalty financing obligation of $81.8 million and senior secured convertible notes of $59.2 million. The company states that existing cash resources are expected to fund planned operations for at least the next 12 months.
Milestone Pharmaceuticals reported its first quarter of commercial sales for CARDAMYST, its newly approved nasal spray for paroxysmal supraventricular tachycardia, generating $0.2 million in product revenue for the three months ended March 31, 2026. The company remains in an investment phase, with a net loss of $26.1 million compared with $20.8 million a year earlier, driven mainly by higher commercial spending.
Milestone ended the quarter with cash, cash equivalents and short-term investments of $184.2 million, and believes this balance will fund planned operations for at least 12 months. During the quarter it received $75 million from a royalty financing tied to future U.S. CARDAMYST sales and raised additional equity via an at-the-market program and warrant exercises, while continuing development of etripamil for atrial fibrillation with rapid ventricular rate.
Milestone Pharmaceuticals (MIST) filed its Q3 2025 10‑Q. The company reported a net loss of $11.9 million for the quarter and $45.6 million for the nine months. Operating expenses reflected continued R&D and growing commercial preparation, with quarterly R&D of $3.9 million, G&A of $3.3 million, and commercial spend of $4.6 million.
Liquidity strengthened after a July equity and warrant financing, bringing net proceeds of $48.6 million. Cash, cash equivalents and short‑term investments totaled $82.6 million as of September 30, 2025, and management expects liquidity to support operations for at least 12 months. Q3 operating cash outflow was part of year‑to‑date cash used in operations of $36.3 million.
Following a March 2025 Complete Response Letter for CARDAMYST (etripamil) in PSVT, the FDA accepted the company’s resubmission with a PDUFA target date of December 13, 2025. Senior secured convertible notes had a net carrying amount of $56.2 million. Common shares outstanding were 85,169,344 as of September 30, 2025.
Milestone Pharmaceuticals (MIST) delivered a mixed quarterly update focused on advancing its lead candidate, etripamil, while absorbing higher operating losses. For the six months ended June 30, 2025 the company reported a net loss of $33.7 million (net loss per share $0.51) and an accumulated deficit of $401.3 million. As of June 30, 2025, Milestone held $42.5 million in cash and $0.9 million in short-term investments (total ~$43.4 million) and reported total assets of $47.4 million and total liabilities of $65.2 million, including $55.2 million in senior secured convertible notes.
The FDA issued a Complete Response Letter in March 2025 citing CMC and inspection items but accepted Milestone’s June 13, 2025 response and set a PDUFA target date of December 13, 2025. A July 11, 2025 underwritten offering subsequently provided approximately $48.7 million of net proceeds and the RTW royalty agreement marketing deadline was extended to December 31, 2025. NODE-303 data showed a median time-to-conversion of 17 minutes with generally favorable tolerability. The company reported no revenue for the periods presented.